EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dual Targeted Therapy as a Treatment Strategy for Refractory Psoriatic Arthritis: Real‐World Effectiveness and Safety From a Prospective Cohort

André Lucas Ribeiro iD, Zahra Al-Zahir iD, Virginia Carrizo Abarza iD, Khalad Maliyar iD, Siddhartha Sood iD, Ahmed Bagit, Muskaan Sachdeva, Sahil Koppikar iD, Dafna D Gladman iD, Jensen Yeung iD, Vinod Chandran iD, Lihi Eder iD

ACR Open Rheumatology · 2026-08 · 8 (8)

DOI: 10.1002/acr2.90084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 10.08.2026. Verfasst von André Lucas Ribeiro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Moinhos de Vento, Porto Alegre, Brazil. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canada Research Chair in Inflammatory Rheumatic Diseases (Tier 2), Dr. Dafna D. Gladman Chair in Psoriatic Arthritis Research, Johnson & Johnson Fellowship grant.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To describe patient profiles, treatment patterns, clinical outcomes, and safety of intentional dual biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD) therapy in psoriatic arthritis (PsA). A subset of patients with PsA continue to experience persistent inflammation despite b/tsDMARD monotherapy. Dual b/tsDMARD therapy has emerged as a potential strategy in refractory cases, but evidence in PsA remains limited.

Methods

We conducted a nested study within the International Psoriasis and Arthritis Research Team prospective cohort. Adults satisfying Classification Criteria for Psoriatic Arthritis who received two concurrent b/tsDMARDs (TNFi, IL‐17i, IL‐23i, JAKi, TYK2i, with or without apremilast) for ≥60 days were included. Baseline features, previous therapies, indications for dual therapy, and disease activity measures (tender joint count in 68 joints, swollen joint count in 66 joints, Disease Activity Index for Psoriatic Arthritis [DAPSA], Psoriasis Area and Severity Index [PASI], body surface area, patient visual analog scale) were collected. Clinical outcomes were reassessed at three‐ to six‐month intervals, with effectiveness assessed only for dual bDMARD + JAK/TYK2i combinations. Safety was evaluated through all‐cause adverse events.

Results

Thirty‐nine patients initiated dual therapy: 24 patients received bDMARD + JAK/TYK2i and 15 patients with bDMARD + apremilast. Patients were highly treatment‐experienced (median two conventional synthetic DMARDs and five b/tsDMARDs). Indications included refractory peripheral arthritis, concurrent joint and skin activity, palmoplantar or nail psoriasis, and persistent enthesitis. Among bDMARD + JAK/TYK2i combinations, improvements were observed in joint counts, DAPSA, PASI, and patient‐reported outcomes. Adverse events were infrequent and mild.

Conclusions

In this real‐world cohort, dual b/tsDMARD therapy was feasible, well‐tolerated, and associated with clinical improvement in patients with refractory PsA. These findings support its individualized use and highlight the need for controlled studies to define long‐term safety and optimal combination strategies.

Autor:innen und Institutionen

  • Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
  • Women's College Research Institute, Toronto, Ontario, Canada.
  • Department of Medicine and Institute of Medical Science, University of Toronto, Ontario, Canada.
  • Gladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.
  • Division of Dermatology, Department of Medicine, University of Toronto, Ontario, Canada.

ORCID-Profile: André Lucas Ribeiro, Zahra Al-Zahir, Virginia Carrizo Abarza, Khalad Maliyar, Siddhartha Sood, Sahil Koppikar, Dafna D Gladman, Jensen Yeung, Vinod Chandran, Lihi Eder

Förderung

  • Canada Research Chair in Inflammatory Rheumatic Diseases (Tier 2)
  • Dr. Dafna D. Gladman Chair in Psoriatic Arthritis Research
  • Johnson & Johnson Fellowship grant

Zitieren

APA

Lucas Ribeiro, A., Al-Zahir, Z., Carrizo Abarza, V., Maliyar, K., Sood, S., Bagit, A., Sachdeva, M., Koppikar, S., Gladman, D. D., Yeung, J., Chandran, V., & Eder, L. (2026). Dual Targeted Therapy as a Treatment Strategy for Refractory Psoriatic Arthritis: Real‐World Effectiveness and Safety From a Prospective Cohort. ACR Open Rheumatology, 8(8). https://doi.org/10.1002/acr2.90084

Vancouver

Lucas Ribeiro A, Al-Zahir Z, Carrizo Abarza V, Maliyar K, Sood S, Bagit A, et al. Dual Targeted Therapy as a Treatment Strategy for Refractory Psoriatic Arthritis: Real‐World Effectiveness and Safety From a Prospective Cohort. ACR Open Rheumatology. 2026;8(8). doi:10.1002/acr2.90084

BibTeX
@article{LucasRibeiro2026,
  author = {Lucas Ribeiro, André and Al-Zahir, Zahra and Carrizo Abarza, Virginia and Maliyar, Khalad and Sood, Siddhartha and Bagit, Ahmed and Sachdeva, Muskaan and Koppikar, Sahil and Gladman, Dafna D and Yeung, Jensen and Chandran, Vinod and Eder, Lihi},
  title = {Dual Targeted Therapy as a Treatment Strategy for Refractory Psoriatic Arthritis: Real‐World Effectiveness and Safety From a Prospective Cohort},
  journal = {ACR Open Rheumatology},
  year = {2026},
  volume = {8},
  number = {8},
  doi = {10.1002/acr2.90084}
}
Kostenlos starten →